Protagonist says FDA approves Takeda’s MIMRYLO for polycythemia vera erythrocytosis - PTGX News | RalliesProtagonist says FDA approves Takeda’s MIMRYLO for polycythemia vera erythrocytosis
P
PTGX• FDA approval and deal economics
- FDA cleared Takeda’s MIMRYLO (rusfertide) for erythrocytosis in adults with polycythemia vera.
- Protagonist will receive $275 million in milestone payments tied to the approval.
- The deal includes 14%–29% tiered royalties on worldwide net sales, with up to $875 million in additional potential milestones.
